Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

August 1, 2008 Approval Letter - Fluvirin

Our STN: BL 103837/5358

August 1, 2008

Novartis Vaccines and Diagnostics Limited
Attn: Lisa Bissett
Gaskill Road
Liverpool L24 9GR
United Kingdom

Dear Ms. Bissett:

We have approved your request to supplement your Biologics License Application for Influenza Vaccine, Fluvirin®, to include the 2008-2009 United States formulation for vaccine produced at the Liverpool, UK--------------------------.

Please submit all final printed labeling at the time of use and include implementation information on FDA form 356h. Please provide PDF-format electronic copies of these labels. We will include the information contained in the above referenced supplement in your Biologics License Application file.

Sincerely yours,

/Jerry Weir/

Jerry Weir, Ph.D.
Division of Viral Products
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research

Attachment: Approved Final Draft Labeling

Return to product page

Page Last Updated: 03/30/2009
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English